Shengqing Jiangzhuo capsule alleviates intestinal inflammation in chronic kidney disease
SQJZ alleviates CKD-associated intestinal inflammation by inhibiting CHAC1 to inactivate the HIF-1 pathway, positioning SQJZ as a promising gut-targeted therapy in CKD.